REVIEW

Exploring NFκB pathway as a potent strategy to mitigate COVID-19 severe morbidity and mortality

Mubarak Muhammad1 | Tasneem M. Hassan2 | Sani S. Baba3 | Mustapha I. Radda3 | Mubarak M. Mutawakkil4 | Majida A. Musa4 | Sazal AbuBakar5 | Shih Keng Loong5 | Ibrahim Yusuf6

1Department of Physiology, College of Medicine, University of Ibadan, Nigeria
2Department of Physiotherapy, Aminu Kano Teaching Hospital, Kano, Nigeria
3Department of Human Physiology, College of Health Sciences, Bayero University Kano, Nigeria
4Pharmacology and Therapeutics, College of Health Sciences, Bayero University Kano, Nigeria
5Tropical Infectious Diseases Research and Education Centre, Higher Institution Centre of Excellence, Universiti of Malaya, Kuala Lumpur, Malaysia
6Department of Pathology, Aminu Kano Teaching Hospital, Kano, Nigeria

Abstract
The pandemic of coronavirus disease 2019 (COVID-19), for which there does not appear to be an approved cure, the primary treatment options consist of non-pharmacological preventive measures and supportive treatment that are aimed at halting the progression of the disease. Nuclear factor kappa B (NFκB) presents a promising therapeutic opportunity to mitigate COVID-19-induced cytokine storm and reduce the risk of severe morbidity and mortality resulting from the disease. However, the effective clinical application of NFκB modulators in COVID-19 is hampered by a number of factors that must be taken into consideration.

This paper therefore explored the modulation of the NFκB pathway as a potential strategy to mitigate the severe morbidity and mortality caused by COVID-19. The paper also discusses the factors that form the barrier, and it offers potential solutions to the various limitations that may impede the clinical use of NFκB modulators against COVID-19.

This paper revealed and identified three key potential solutions for the future clinical use of NFκB modulators against COVID-19. These solutions are pulmonary tissue-specific NFκB blockade, agents that target common regulatory proteins of both canonical and non-canonical NFκB pathways, and monitoring clinical indicators of hyperinflammation and cytokine storm in COVID-19 prior to using NFκB modulators.

Keywords: COVID-19, SARS-CoV-2, NFκB, cytokine storm.
INTRODUCTION

Coronavirus disease 2019 (COVID-19) pandemic, the current unfolding primary disease of respiratory system that occurs due to infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen and resulting in acute respiratory distress syndrome (ARDS), remains a plague that poses greatest global challenge to every aspect of humans’ life with no definite end in sight as therapeutic cure at the moment.\(^1\)\(^2\) The clinical manifestation of COVID-19 variably range from asymptomatic to severe cases, with severity associated with lethal and life threatening consequences such as intense pneumonia, ARDS, respiratory failure, septic shock, multiple organ failure and mortality.\(^3\)\(^4\)

There are three main factors that made COVID-19 a challenging and dreadful disease; first is the absence of definitive cure;\(^5\)\(^6\) secondly the high infection rate of COVID-19 ascribed to SARS-CoV-2 increased affinity for ACE2 cognate receptor relative to other coronaviruses that cause lower respiratory tract infections;\(^8\) third is the severe morbidity and mortality due to the disease attributed to cytokine storm.\(^9\)\(^10\) The hallmark of cytokine storm in COVID-19 is aberrant and excessive generation of pro-inflammatory cytokines due to loss of regulatory control mechanism in the host immune response to SARS-CoV-2 infection.\(^11\) Pulmonary host immune cells generate an increase in pro-inflammatory cytokine production necessary to coordinate immune response to SARS-CoV-2 virus. Ideally, after generation of these cytokines and elimination of the virus, homeostasis regulatory mechanisms are activated aimed at returning the immune cells to basal state through generation of anti-inflammatory cytokines and host tissue repair mechanism. Conversely, if SARS-CoV-2 triggers dysfunctional immune response termed immunopathology, the homeostasis control mechanism becomes lost resulting in cytokine storm.\(^12\)\(^13\)

According to the data from World Health Organization (WHO) and John Hopkins University, the worldwide number of confirmed cases and mortality from COVID-19 were 15,090,000 and 768,600 respectively as at 16 August 2020. Clinical studies among SARS-CoV-2 infected patients have shown that cytokine storm is the principal cause of severe morbidity, poor prognosis and mortality due to COVID-19.\(^14\) Persistent marked elevation of 38 out of 48 cytokines levels measured in a longitudinal study of COVID-19 patients was observed in these patients.\(^15\) A report from cohort of 50 COVID-19 patients with severe with severe morbidity revealed that excessive production of cytokines; tumor necrosis alpha (TNF-\(\alpha\)) and interleukin 6 (IL-6) caused by excessive activation of nuclear factor kappa B (NF\(\kappa\)B) transcriptional activity, coupled with impaired interferon (IFN) activity were responsible for severe morbidity due to COVID-19.\(^16\) This investigation therefore suggests combined therapeutic strategy that attenuates TNF-\(\alpha\) and/or IL-6 coupled with IFN as possible strategies to effectively attenuate COVID-19 severe morbidity and mortality. Several therapeutic agents and strategies aimed to reduce severe morbidity and mortality due to COVID-19 through mitigating cytokine storm and hyperinflammation have been considered. Pharmacological agents such as selective cytokine blockers (TNF blockers, IL-6 antagonists, IL-1 family antagonists), corticosteroids, toll-like receptor antagonists, janus kinase inhibitors, chloroquine and hydroxychloroquine, and ulinastatin have all been identified and considered as promising agents. Therapeutic strategies through interferon therapy, convalescent plasma therapy, stem cells therapy, and blood purification therapy have also been recognized.

A therapeutic opportunity to be explored is provided by NF\(\kappa\)B that serves as major transcriptional factor in stimulation of cytokines genes in SARS-CoV-2 induced cytokine storm. Activation of the NF\(\kappa\)B signaling pathway represents a major contribution in SARS-CoV-2 induced cytokine storm and NF\(\kappa\)B is

Supplementary information The online version of this article (Tables/Figures) contains supplementary material, which is available to authorized users.

Corresponding Author: Mubarak Muhammad, Department of Physiology, College of Medicine, University of Ibadan, Ibadan, Nigeria. Email: mubarakmahmad@yahoo.com
well established as major transcriptional gene regulator that induces the expression of almost 400 target genes involved in inflammation in response to appropriate production stimuli.\textsuperscript{17,18} However, a number of factors form limitations that challenge the pre-clinical translation of NF\textsubscript{κ}B modulators to clinical management of various disease conditions, including COVID-19. The objective of this paper therefore is to explore the modulation NF\textsubscript{κ}B pathway as a strategy to mitigate COVID-19 severe morbidity and mortality, as well as discuss and offer potential solutions to various limitations that might challenge the clinical use of NF\textsubscript{κ}B modulators against COVID-19.

Cytokine storm in COVID-19 and agents that target it

Cytokine storm also known as hypercytokinemia is the excessive inflammatory reaction due to exaggerated uncontrolled response of the host’s immune system.\textsuperscript{19}The term cytokine storm was first used by Ferrara et al.\textsuperscript{20} to denote exaggerated cytokine production in a graft-versus-host disease where the role of interleukin 1 was considered. Cytokine storm was first implicated in an infectious disease by Barry et al\textsuperscript{21} 2000 in Epstein-Barr virus-associated study and subsequently many infectious and non-infectious diseases have been linked with cytokine storm, including severe acute respiratory syndrome coronavirus (SARS-CoV)\textsuperscript{22} and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\textsuperscript{23,24}

The mechanism of cytokine storm in COVID-19 results from loss of regulatory control in the host immune response subsequent to SARS-COV-2 invasion and replication. The host resident cells of the innate immunity in the lungs such as alveolar macrophages, epithelial cells and dendritic cells,\textsuperscript{25} and the antigen presenting cells which are components of the adaptive immunity constituted by T and B lymphocytes,\textsuperscript{19} requires ideal activation of the inflammatory pathways through cytokine and chemokine production as key components necessary for viral elimination. This well-regulated process proceeds to play an important protective role that leads to the resolution and elimination of the virus.\textsuperscript{26}

Nonetheless, dysfunctional pulmonary immune response occurs in cases of SARS-CoV-2 infections where the immune response becomes exaggerated resulting in the loss of regulatory control mechanism of cytokines generation\textsuperscript{27,28} with concomitant elevation in levels of pro-inflammatory cytokines resulting in significant tissue injury at both local and systemic levels. At pulmonary level, this leads to increased permeability of the alveoli resulting in unrestrained inflammatory cell infiltration and accumulation of fluids that result in physiologic alteration of alveolar gas exchange.\textsuperscript{29} At systemic level, abnormally high levels of cytokines impair host response to infection that translates into sepsis culminating into septic shock and multi-organ failure.\textsuperscript{30}

Several studies analyzing cytokine profile from COVID-19 patients has shown that cytokine storm correlated directly with poor prognosis and severity of COVID-19.\textsuperscript{31,32} Studies have been consistent in establishing relationship between cytokine levels and disease progression in patients with COVID-19. COVID-19 patients in the intensive care unit (ICU) were found to have higher serum levels of macrophage inflammatory protein-1A, and TNF-\textsubscript{α} compared with COVID-19 patients from general wards indicating that cytokine storm is positively correlated with disease severity.\textsuperscript{2} Serum level of IL-6 and the expression levels of IL-2R in COVID-19 patients were found to be positively correlated with the severity of the disease.\textsuperscript{24} Positive regulatory loop that amplify local inflammation, including production of IL-6 and TNF-\textsubscript{α} generated by NF\textsubscript{κ}B pathway was implicated as one of the major genesis of severe form of COVID-19.\textsuperscript{16}

Effective cytokine storm suppression has been suggested as modality for therapeutic intervention in severe COVID-19 infection to curtail mortality.\textsuperscript{33} Various therapeutic agents and strategies been considered against SARS-CoV-2 induced cytokine storm. These includes selective cytokine blockers (TNF blockers, IL-6 antagonists, IL-1 family antagonists),\textsuperscript{34–37} corticosteroids,\textsuperscript{38,39} interferon therapy,\textsuperscript{38,39} stem cells,\textsuperscript{40} convalescent plasma therapy,\textsuperscript{41} blood purification therapy,\textsuperscript{38} Janus kinase inhibitors,\textsuperscript{42} toll-like receptor antagonist,\textsuperscript{43} chloroquine and hydroxychloroquine (CQ/HCQ),\textsuperscript{44,45} ulinastatin\textsuperscript{46} among others. A clinical trial group termed RECOVERY (Randomized Evaluation of COVid-19 thERapY) has of recent approved the use of dexamethasone, a
NFκB PATHWAY TO MITIGATE COVID

corticosteroid as a potent agent to improve survival in COVID-19, as it was found to reduce death by up to one third in hospitalized patients with severe respiratory complications of COVID-19.47

NFκB pathway and its blockers
NFκB belongs to Rel family of proteins and is one of key transcription factor which signaling pathway activates transcription of several genes involved in inflammation and cellular immunity.48 The NFκB signaling pathway is initiated by the presence of wide range inflammatory stimuli as a result of infections, injury or oxidative stress. NFκB is sequestered in the cytoplasm coupled to its inhibitory proteins collectively called Inhibitors of NFκB (IκB), with the prominent being Inhibitor of NFκB alpha (IκB-α) which inhibits the translocation to the nucleus and hence the activation of NFκB.49 Presence of appropriate NFκB production signal leads to activation of cytosolic enzyme IκB kinase (IKK) that subsequently triggers the proteolytic degradation of IκB through enzymatic phosphorylation, thus cleaving NFκB from its inhibitors freeing it to subsequently translocate to the nucleus, where it binds with DNA and activates transcription of cytokines, chemokines, inflammatory enzymes, and adhesion molecules among others.50 IKK is an enzyme complex constituted by two related kinases namely IκB kinase alpha (IKKα) and IκB kinase beta (IKKβ), and a regulatory non-enzymatic scaffold protein termed NFκB essential modifier (NEMO) also known as IKKγ.51

Activated NFκB complexes can be of any form of homo- and heterodimers subunits, based on the subunit dimmers released upon enzymatic activity of IKK; NFκB signaling pathway is classified into canonical (classical) pathway and the non-canonical (alternative) pathway.51,52 The classical pathway is most common and IKK degradation of IκB leads to the release p50/p65 dimers that translocate to the nucleus to induce downstream transcriptional activity.53,54 In this pathway signals are mostly received from the receptors such as tumor necrosis factor receptor (TNF-R), interleukin 1 receptor (IL-1R) and toll-like receptors.55 The non-canonical pathway is less common and IKK enzymatic phosphorylation activity leads to release of p100 which subsequently liberate RelB/p52 active heterodimers that translocate to the nucleus to activate target genes.56 This pathway is activated by limited stimuli, mainly from lymphotakin B and B-cell activating factor.57

Several literatures support and expand the physiological role of NFκB in numerous biological systems including immune responses, inflammation, antioxidant proteins in oxidative stress, cell growth and apoptosis.58–60 Dysregulated NFκB activation and its signaling pathway has played a role in the pathogenesis of several disease conditions such as autoimmune diseases,61 malignancies,62,63 neurodegenerative diseases,64,65 musculoskeletal diseases,66 and microbial diseases including infectious diseases of respiratory system caused by viruses in influenza,67,68 respiratory syncytialvirus,69 SARS-CoV,70 SARS-CoV-2.71,72

Cytokine storm in COVID-19 and NFκB pathway
Cytokine storm in COVID-19 has been one of the major therapeutic targets aimed at reducing severity of morbidity and mortality due to SARS-CoV-2 infection. All patients with severe COVID-19 are required and recommended for laboratory test to screen hyperinflammation and possible cytokine storm syndrome.36 Several pharmacological agents for therapeutic use against COVID-19 induced cytokine storm has been considered, with each targeted to suppress cytokine storm and attenuate severe morbidity and mortality due to the disease. Theoretical mechanism of action of such pharmacological agents and strategies has been explained. Selective cytokine blockers such as TNF blockers, IL-1 family antagonists (anakinra), and IL-6 antagonists (monoclonal antibody IL-6 receptor antagonist tocilizumab, sarilumab) directly inhibit the respective pro-inflammatory cytokine.36,37 Corticosteroids (methylprednisolone, dexamethasone, and hydrocortisone) possess steroid hormones-like effect of suppressing inflammation.38,39 Interferons (IFN-α, IFN-λ) confer anti-inflammatory property by acting on epithelial cells to inhibit mononuclear macrophage-mediated pro-inflammatory activity of IFN-α,β signaling pathway.38 Stem cells (mesenchymal stem cells) offer anti-inflammatory effect through targeting and inhibiting abnormal activation of inflammatory cells such as macrophages.40 Convalescent
plasma or intravenous immunoglobulins serves as antibodies to salvage and facilitate infected cell immune clearance. Blood purification strategies aimed at removing inflammatory factors and minimize damage due to hyperinflammation.

Other pharmacological agents include Janus kinase (JAK) inhibitors (tofacitinib) which interfere with JAK signaling that activates transcription and induction of inflammatory cytokines such as IL-6 thereby interfering with its production. Toll-like receptors (TLR1-11) antagonists interfere with TLR mediated critical role in activation of inflammatory pathways involving TLR transmembrane that activate innate immunity by recognizing pathogen associated molecular patterns. CQ/HCQ have multifaceted anti-inflammatory mechanism including inhibition of IL-6 and TNF-α and suppression of TNF receptors, suppression of major histocompatibility complex (MCH) class II expression which obstructs T-cell activation and consequent expression of CD145 and cytokines release, and to a certain extent through obstruction of Toll-like receptors (TLRs) signaling among others to support its proposed advantage for clinical use. Ulinastatin glycoprotein inhibits pro-inflammatory cytokines including interleukins (IL-1, IL-6 and IL-8), and TNF-α as one of its principle therapeutic mechanism of action to reduce ARDS and mortality.

It is a very imperative and wise approach to explore modulation of NFκB pathway as potential strategy to mitigate COVID-19 severe morbidity and mortality. This is based on the fact that NFκB pathway control the expression of numerous genes activated during inflammation such as genes for pro-inflammatory cytokines, chemokines, immune receptors, cellular ligands, adhesion molecules, metalloproteinases, acute phase proteins, and inflammatory enzymes. This makes NFκB master regulator and most important transcription factor that plays a fundamental role in inducing wide spectrum genes involved in inflammation. Thus, inhibition of NFκB pathway offers exceptional advantage of multi-levels downstream effect towards mitigating hyperinflammation and ultimately cytokine storm in COVID-19 when compared with other agents that targets single host regulatory pathway. There exist abundant of NFκB pathway blockers with more than 750 been identified, but limitation exists in the preclinical translation of such blockers to clinical practice. A number of factors culminate to form a barrier against the effective clinical use of NFκB pathway blockers. Firstly, lack of specificity by NFκB blockers to spare other cellular physiological functions in the biological system orchestrated by NFκB thereby rendering numerous adverse effects from indiscriminate NFκB blockade. Secondly, the multitude complexity of NFκB pathway signaling that serves as double-edged sword, while on one hand this complexity serves as an advantage for pharmacological agents to target different steps of the pathway as therapeutic options, on the other hand it serves as a disadvantage of possibilities to sparing NFκB activities through shunting a particular mechanism targeted through other available pathways or dimers. Thirdly, the therapeutic time window for clinical administration of NFκB blockers that requires appropriate determination of disease progression to warrant the use in order to avoid hindering the NFκB mediated critical role in fighting the diseases.

Despite the aforementioned limitations that challenge the effective translational use of NFκB pathway blockers in clinical management of various diseases including COVID-19, there is still reasonable hope to consider in their use as therapeutic agents. Future research and investment into the development of tissue-specific or cell-specific NFκB blockers such as pulmonary tissue-specific NFκB blockade as in the case of COVID-19 might present promising strategy to minimize or avoid the unwanted side effects of non-selective NFκB blockade. Such NFκB blockers should target common regulatory proteins of both canonical and noncanonical NFκB pathways as a way to curtail shunting of the therapeutic agent through the alternate NFkB pathway. Monitoring clinical indicators of disease severity and monitoring laboratory indices of disease progression through serial tests that may herald the onset of hyperinflammation and cytokine storm in COVID-19 might provide the necessary information on dysregulation of host immunity thus providing appropriate therapeutic timing for clinical drug administration.
NFκB PATHWAY TO MITIGATE COVID

CONCLUSIONS

Non-pharmacological preventive strategies and supportive treatment remains the mainstay of management approach in COVID-19 pandemic as there appears to be no silver bullet for therapeutic cure at the moment. NFκB pathway represents a multi-level regulator of numerous genes involved in COVID-19 induced cytokine storm, thus making development of cell or tissue targeted NFκB blockers potentially promising therapeutic agents against severe morbidity and mortality in COVID-19 patients.

Future research should address the aforementioned strategies in order to circumvent the factors militating against the clinical use of NFκB blockers against COVID-19.

INFORMATION

Acknowledgements. This study was supported by the Ministry of Higher Education, Malaysia under the Higher Institution Centre of Excellence Program, MO002-2019 and the Universiti Malaya under the research university program, RU006-2021.

Contributions. The authors contributed equally.

Conflict of interest. The authors declare no potential conflict of interest.

Funding: Ministry of Higher Education, Malaysia (MO002-2019) and Universiti Malaya (RU006-2021).

REFERENCES

1. Berg MK, Yu Q, Salvador CE. Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19. Science Advances. 2020;p. 1–9.

2. Huang C, Wang Y, Li Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.

3. Labban L, Thallaj N, Labban A. Assessing the level of awareness and knowledge of covid 19 pandemic among Syrians. Archives of Medicine. 2020;12:1–8.

4. Yang X, Yu Y, Xu J. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;p. 1–7.

5. Zheng J, Sars. CoV-2: an emerging coronavirus that causes a global threat. International Journal of Biological Sciences. 2020;16:1678–1685.

6. Singhal T. A review of coronavirus disease-2019 (COVID-19). The Indian Journal of Pediatrics. 2020;87:281–286.

7. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E. Clinical laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Medicine and Infectious Disease. 2020;p. 1–13.

8. Tay MZ, Poh CM, Rénia L. The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology. 2020;20:363–374.

9. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity. 2020;109.

10. Fung S, Yuen K, Ye Z. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerging Microbes & Infections. 2020;9:558–570.

11. Tang Y, Liu J, Zhang D. Cytokine storm in COVID-19: the current evidence and treatment strategies. Frontiers in Immunology. 2020;22:1–13.

12. Bhaskar S, Sinha A, Banach M. Cytokine storm in Covid 19- immunopathological mechanisms, clinical considerations, and therapeutic approaches: The reprogram consortium position paper. Frontiers in Immunology. 2020;11:1648–1648.
13. Sinha P, Matthey MA, Calfee CS. Is a “cytokine storm” relevant to COVID-19? JAMA Internal Medicine. 2020;

14. Ruan Q, Wang YK, W. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020;46:846–854.

15. Huang H, Cai S, Li Y. Prognostic factors for COVID-19 pneumonia progression to severe symptom based on the earlier clinical features: a retrospective analysis. medRxiv. 2020;

16. Hadjadj J, Yatim N, Barnabei L. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;p. 1–14.

17. Chen F, Bower J, Demers JM. Upstream signal transduction of NF-kB activation. Atlas of Genetics and Cytogenetics in Oncology and Haematology. 2002;6:345–69.

18. Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y AcadSci. 2005;1056:218–251.

19. Ragab D, Eldin HS, Taeimah M. The covid-19 cytokine storm; what we know so far. Frontiers in Immunology. 2020;11:1–4.

20. Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc. 1993;25:1216–1217.

21. Barry SM, Johnson MA, Janossy G. Cytopenia or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited. Bone Marrow Transplant. 2000;26:591–597.

22. Huang KJ, Su I, Theron M. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2005;75:185–194.

23. Chen G, Wu D, Guo W. Clinical and immunological features in severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–2629.

24. Chen L, Liu H, Liu W. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chinese Journal of Tuberculosis and Respiratory Diseases. 2020;43:203–208.

25. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clinical Immunology. 2020;215:1–7.

26. Ullah A, Araf Y, Sarkar B; 2020. Available from: https://doi.org/10.20944/preprints202004.0372.v1.

27. Liu Y, Zhang C, Huang F.; Available from: http://www.chinaxiv.org/abs/202002.00018.

28. Chen C, Zhang XR, Ju ZY. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. ZhonghuaShaoxhangZazhi. 2020;36:5–5.

29. Rockx B, Kuiken T, Herfst S; 2020. Available from: https://doi.org/10.1101/2020.03.17.995639.

30. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. International Journal of Cardiology. 2020;

31. Gao Y, Li T, Han M. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92:791–796.

32. Sun D, Li H, Lu X. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World J Pediatr. 2020;19:1–9.

33. Wan S, Yi Q, Fan S.; Available from: https://doi.org/10.1101/2020.02.10.20021832.

34. Feldmann M, Maini NR, Woody NJ. Trials of anti-tumor necrosis factor therapy for COVID-19 are urgently needed. The Lancet. 2020;395:30858–30866.
NFκB PATHWAY TO MITIGATE COVID

35. Convertino I, Tuccori M, Ferraro S. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Critical Care. 2020;24:331–331.

36. Mehta P, Mcauley DF, Brown M. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395:1033–1034.

37. Cao X. COVID-19: immunopathology and its implications for therapy. Nature Reviews Immunology. 2020;20:269–270.

38. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. Journal of Infection. 2020;80:607–613.

39. Rosa S, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Pan American Health Organisation. 2020;44.

40. Shi Y, Wang Y, Shao C. COVID-19 infection: the perspectives on immune responses. Cell Death & Differentiation. 2020;27:1451–1454.

41. Sanders J, Monogue ML, Jodlowski TZ. Pharmacologic treatments for coronavirus disease 2019 (covid-19) a review. JAMA. 2020;323:1824–1836.

42. Lannaccone G, Scacciavillani R, Buono M. Weathering the cytokine storm in COVID-19: therapeutic implications. Cardiorenal Med. 2020;.

43. Birra D, Benucci M, Landolfi L. COVID 19: a clue from innate immunity. Immunologic Research. 2020;68:161–168.

44. Gautret P, Lagier J, Parola P. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 2020;56.

45. Saqrane S, Mhammedi MAE. Review on the global epidemiological situation and efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19. New Microbes and New Infections. 2020;35.

46. Qia A, Wua Y, Dong N. Recombinant human ulinastatin improves immune dysfunction of dendritic cells in septic mice by inhibiting endoplasmic reticulum stress-related apoptosis. International Immunopharmacology. 2020;85.

47. Horby P, Lim WS, Emberson J. Effect of dexamethasone in hospitalized patients with COVID-19 - preliminary report. medRxiv. 2020;p. 1–14.

48. Aronowski J, Zhao X. Molecular pathophysiology of cerebral hemorrhage: Secondary brain injury. Stroke. 2011;42:1781–1786.

49. Berlo DV, Knaapen AD, Schooten RP. NFκB dependent and independent mechanisms of quartz-induced proinflammation activation of lung epithelial cells. Particle Fibre Toxicology. 2010;7:1–20.

50. Oeckinghaus A, Ghosh S. The NFκB family of transcription factors and its regulation. Cold Spring Harbor Perspective. Biology. 2009;1:1–14.

51. Grumolato L, Liu G, Mong P. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Development. 2010;24:2517–2530.

52. Sun SC. The non-canonical NF-KB pathway and inflammation. Nat Rev Immunol. 2017;17(9):545–558.

53. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends in Immunology. 2004;25:280–288.

54. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25:6680–6684.

55. Tornatore L, Thotakura AK, Bennett J. The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends in Cell Biology. 2012;22:557–566.
56. Tergaonkar V. NFkB pathway: A good signaling paradigm and therapeutic target. Int J Biochem Cell Biol. 2006;38:1647–1653.

57. Scheidereit C. IkB kinase complexes: gateways to NFkB activation and transcription. Oncogene. 2006;25:6685–6705.

58. Liao Q, Ye L, Timani KA. Activation of NF-κB by the full-length nucleocapsid protein of the SARS coronavirus. ActaBiochimicaetBiophysicaSinica. 2005;37:607–612.

59. Vitiello M, Galdiero M, Finamore E. NF-kB as a potential therapeutic target in microbial diseases. Molecular BioSystem. 2012;8:1108–1120.

60. Vrankova S, Barta A, Klimentova J. The regulatory role of nuclear factor kappa B in the heart of hereditary hypertriglyceridemicrat. Oxidative Medicine and Cellular Longevity. 2016;p. 1–6.

61. Herrington FD, Carmody RJ, Goodyear CS. Modulation of NF-κB signaling as a therapeutic target in autoimmunity. Journal of Biomolecular Screening. 2016;21:223–242.

62. Biswas DK, Dai S, Cruz A. The nuclear factor kappa B (NF-kB): A potential therapeutic target for estrogen receptor negative breast cancers. PNAS. 2001;98:10386–10391.

63. Plewka D, Plewka A, Miskiewicz A. Nuclear factor-kappa B as potential therapeutic target in human colon cancer. J Can Res Ther. 2018;14:516–536.

64. Yan J, Greer JM. NF-kB, a potential therapeutic target for the treatment of multiple sclerosis. CNS & Neurological Disorders - Drug Targets. 2008;7:536–557.

65. Jha NK, Jha SK, Kar R. Nuclear factor-kappa B as a therapeutic target for Alzheimer’s disease. Journal of Neurochemistry. 2019;150:113–137.

66. Roman-Blas JA, Jimenez SA. NF-kB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. OsteoArthritis and Cartilage. 2006;14:839–848.

67. Pinto R, Herold S, Cakarova L. Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. Antiviral Research. 2011;92:45–56.

68. Wiesener N, Zimmer C, Jarasch-Althof N. Therapy of experimental influenza virus infection with pyrrolidinedithiocarbamate. Med Microbiology. 2011.

69. Zang N, Xie X, Deng Y. Resveratrol-mediated gamma interferon reduction prevents airway-inflammation and airway hyperresponsiveness in respiratory syncytialvirus-infected immunocompromised mice. J Virol. 2011;85:13061–13068.

70. Dediego ML, Nieto-Torres JL, Regla-Nava JA. Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. Journal of Virology. 2014;88:913–924.

71. Elkhodary M. Treatment of COVID-19 by controlling the activity of the nuclear factor- kappa B. Cell Biology. 2020;9:109–121.

72. Catanzaro M, Fagiani F, Racchi M. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduction and Targeted Therapy. 2020;5:1–10.

73. Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell. 2020;180:1044–66.

74. Zhang X, Zhu Z, Jiao W. Ulinastatin treatment for acute respiratory distress syndrome in China: a meta-analysis of randomized controlled trials. Pulmonary Medicine. 2019;19:196–196.

75. Barnes PJ, Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. The New England Journal of Medicine. 1997;336:1066–1071.
76. Bowie A, Neill O, A L. Oxidative stress and nuclear factor-kB activation: a reassessment of the evidence in the light of recent discoveries. Biochemical Pharmacology. 2000;59:13–23.

77. Shi H, Berger EA. Characterization of site-specific phosphorylation of NF-κB p65 in retinal cells in response to high glucose and cytokine polarization. Mediators of Inflammation. 2018;p. 1–15.

78. Muhammad M. Tumor necrosis factor alpha: a major cytokine of brain neuroinflammation. Croatia: IntechOpen. 2019;p. 1–14.

79. Gilmore TD, Herscovitch M. Inhibitors of NF-κB signaling: 785 and counting. Oncogene. 2006;25:6887–6899.

How to cite this article: Muhammad M., Hassan T.M., Baba S.S., Radda M.I., Mutawakkil M.M., Musa M.A., AbuBakar S., Loong S.K., Yusuf I. Exploring NFκB pathway as a potent strategy to mitigate COVID-19 severe morbidity and mortality. Journal of Public Health in Africa. 2022;13:1679. https://doi.org/10.4081/jphia.2022.1679